Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AntiRetroviral Research fOr Watoto.

X
Trial Profile

AntiRetroviral Research fOr Watoto.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir (Primary) ; Antiretrovirals; Cotrimoxazole; Efavirenz; Lamivudine; Lamivudine/abacavir; Nevirapine; Zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARROW; ARROW
  • Most Recent Events

    • 06 Mar 2024 Results (n=497) assessing associations between CMV Viraemia and mortality in children with HIV in sub-saharan africa were presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 07 Mar 2013 Primary endpoint 'Disease-progression' has been met according to results published in the Lancet; non inferiority of clinical over laboratory monitoring was established.
    • 07 Mar 2013 Primary endpoint 'CD4+-cell-percentage' has not been met according to results published in the Lancet.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top